Per-sample distribution of the identified tier-I-III variants throughout PDAC patients was consistent with data on the molecular pathology of PDAC, which is characterized by either a low tumor mutation burden and a high prevalence of KRAS mutations followed by mutations in TP53, which are relatively late genetic events in the progression model for pancreatic cancer [60]. Here, KRAS is linked to pancreatic neoplasm.